We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
BACKGROUND A large proportion of the elderly population complains of depressive symptoms . The ideal antidepressant for these patients , who often suffer from numerous concomitant diseases , should not worsen their cognitive functions and should be free of contraindications . METHOD To assess the effects of 2 selective serotonin reuptake inhibitors on cognitive functions in elderly depressed patients ( ICD-10 criteria ) , we conducted a double-blind , r and omized , parallel-group , multicenter study comparing paroxetine ( 20 - 40 mg daily ) and fluoxetine ( 20 - 60 mg daily ) treatment for 1 year . Cognitive performance was evaluated by means of the  Buschke Selective Reminding Test  , the  Blessed Information and Memory Test  , the  Clifton Assessment Schedule  , the  Cancellation Task Test  , and the  Wechsler Paired Word Test ;  the  Hamilton Rating Scale for Depression ( HAM-D ) and the Clinical Anxiety Scale were administered to assess the course of depressive and anxiety symptoms , respectively . RESULTS 242 patients were enrolled ( mean + /- SD age = 75.4 + /- 6.6 years ) . During the study , no deterioration of cognition was observed ; on the contrary , most of the tested cognitive functions improved . Good antidepressant efficacy was maintained for over 1 year with both drugs , based on the percentage of responders to treatment ( patients achieving a HAM-D total score < 10 ; 60 % ) . Both drugs showed a good tolerability and safety profile . CONCLUSION The 2 antidepressants proved to be suitable for the long-term treatment of depression in the elderly and to be devoid of detrimental effects on the tested cognitive functions
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .